Trial Profile
A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 14 Jun 2023
Price :
$35
*
At a glance
- Drugs Rimegepant (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Sponsors Biohaven Pharmaceuticals; Pfizer
- 27 Apr 2023 Results from a 52-week, open-label extension phase (n=603) assessing the safety and tolerability of rimegepant 75 mg dosed every other day (EOD) for the preventive treatment of migraine and as-needed (PRN) for acute treatment on nonscheduled dosing days, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
- 27 Apr 2023 Results assessing the effects of rimegepant 75 mg on monthly migraine days (MMDs) through 52 weeks of open-label treatment when dosed every other day (EOD) plus as-needed (PRN) on nonscheduled dosing days, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
- 27 Apr 2023 Results assessing the effects of rimegepant on quality of life over 1-year of open-label treatment, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.